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ABSTRACT 
Background: Influenza, or flu, is a respiratory illness that is caused by a 
virus. As Influenza is known to be highly contagious and there by 
affecting working community at large, a natural; cost effective remedy 
can help sail through the course of illness with much ease.  
The plant Cymbopogon citratus (DC) Stapf. commonly known as Lemon 
grass belongs to Poaceae family and is a native of tropical countries. 
Various studies have been done on the plant to reveal its potential 
therapeutic effects. Thus this study untended to evaluate its efficacy in 
the management of Influenza and its symptoms. 
Methodology: Randomized double blind placebo controlled clinical 
study. 62 patients of age group 20- 50 years, suffering from Influenza and 
fulfilling the diagnostic criteria were selected and randomly grouped into 
trial (Group I - 31 patients) and control group (Group II - 31 patients 
received the Placebo- Distilled water 25ml 3 times daily). Both the 
groups were given Paracetamol 500mg/kg body weight as rescue 
medicine if required.  
Observation & Results: The signs and symptoms of Influenza which 
were exhibited in patients when subjected to the Trial medication 
showed good results. The quality of life in them was better compared to 
control group.  
Conclusion: The current study helped to confirm the effect of the plant 
Cymbopogon citratus (DC) Stapf. in influenza. In Trial group, significantly 
better remission of associated signs and symptoms of influenza was 
found compared to control group. This would help us create an increased 
awareness amongst the public about the use of herbal medicines in either 
cure or as add on therapy in the management of Influenza. 
 
INTRODUCTION 
Influenza mostly referred as flu is an acute 
respiratory illness caused commonly by influenza A 
or B virus. It is one of the worst known pandemics 
which took the life of 50million people. The 
respiratory secretions of infected persons contain 
significant numbers of influenza virus particles, so 
infection can be transmitted by sneezing and 
coughing through large particle droplets[1]. 
The mean period of influenza virus 
shedding in immune competent adult patients is 
about 5 days but may continue for up to 10 days or 
more -especially in children, elderly adults, chronic 
disease patients and immune compromised hosts. 
Typically influenza starts with the abrupt onset of 
high-grade fever, myalgia, headache and malaise. 
These symptoms are followed by symptoms of 
respiratory issues like unproductive cough, sore 
throat or nasal congestion and discharge.  
The illness varies from mild to severe 
suffering, sometimes ending up in complications 
too[2]. As Influenza is known to be highly contagious 
and there by affecting working community at large 
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a natural, cost effective remedy can help sail 
through the course of illness with much ease. 
Cymbopogon citratus (DC.) Stapf. is one such drug 
mentioned in Ayurveda classical texts as an 
antipyretic agent[3]. Many pharmacological studies 
done on this drug have revealed that it possesses 
anti-amoebic, antibacterial, antidiarrheal, anti-
filarial, antimicrobial[4], anti-inflammatory[5], 
antimalarial, anti-mutagenicity, anti-mycobacterial, 
antioxidant, hypoglycemic and neurobehavioral 
properties[6]. In the coastal region of Uttara 
Kannada district this drug is used by labour class 
people for fever. Hence a clinical trial was 
conducted to evaluate the effect of Cymbopogon 
citratus (DC.) Stapf. on its anti-pyretic effects which 
is utmost necessity to benefit public at large. 
Materials and Methods  
1. Study Design: The present study was a 
Randomized, double blind, placebo controlled, 
clinical study.  
2. Data Collection 
Source of clinical data & Drug: A total of sixty 
patients in the age group of 20-50 years suffering 
from influenza and fulfilling the diagnostic criteria 
were selected from Kayachikitsa and other OPD’s of 
Sri Sri College of Ayurvedic Science and Research, 
Bangalore. Arka of Cymbopogan citratus and 
Distilled water were used as the trial drug and 
placebo respectively. 
3. Preparation of Medicine: The drug Cymbopogan 
citratus collected from the herbal garden of college 
was identified and authenticated by the senior 
scientist, taxonomist of the department of PG 
studies Dravyaguna, Sri Sri College of Ayurvedic 
Science and Research, Bangalore. The dosage form 
Arka was prepared at laboratory of Department of 
Dravyaguna using the distillation apparatus in the 
ratio of 1:5 (drug: water). The distilled water was 
prepared using distillation apparatus by means of 
double distillation process. 
4. Grouping: Patients with complaints of fever ≥ 
100.4°F with one respiratory complaint presenting 
within 48 hrs of onset of the condition were 
selected within the age group of 20-50 years of 
either genders.  
5. Recruitment Strategies  
Diagnostic criteria: Patients based on general 
physical examination for classical symptoms of 
influenza, rapid influenza diagnostic test (antigen 
detection) using Nasopharyngeal swab selected. 
Patients with complaints of fever ≥100.4°F with one 
respiratory complaint presenting within 48 hrs of 
onset of the condition were selected.  
Inclusion Criteria: Verified cases of influenza were 
enrolled for the study with fever ≥100.4°F with at 
least one respiratory symptom of influenza which is 
within 48 hrs of onset. 
Exclusion Criteria: Pregnant women, breast 
feeding ladies, suspected bacterial infections, H/o 
antiviral therapy, recent participation in any other 
clinical trial, patients with any other prior illness, 
who have received anti influenza and swine flu 
vaccination, suffering with any chronic diseases and 
high risk cases. 
6. Randomization & Grouping: Randomly patients 
were grouped into trial and control group using 
simple random technique adopting random number 
generator. Group 1 contained 31 patients who 
received the trial drug (Arka of Cymbopogan 
citratus) and Group 2 contained 31 patients who 
received the placebo (distilled water).  
7. Intervention: Written informed consent was 
taken from every patient recruited for the trial. 
Arka and distilled water were both administered in 
the dose of 25ml three times a day orally for a 
period of 5-7 days. Rescue medicine paracetamol 
was advised to be taken by both the groups only on 
having fever or any discomfort.  
8. Assessment Criteria: The fever was recorded in 
degree Fahrenheit and other symptoms were 
recorded in the scoring scale of 10 to 0. Visual 
analogue scale was used to assess pain. 
9. Follow Up and Assessment: alternate days 
follow up was done for 7 days and the findings were 
recorder.  
10. Reporting of Complication/Side Effects/ 
Adverse Events: Proper recording of adverse 
events in the trial group if any was done in the case 
sheet.  
CTRI registration number: Trial REF/2016/10/ 
012456 
Observations 
 A total of 31 patients in both groups in each 
group were enrolled. Group I-31 patients 
received trail drug and Group II-31 patients 
received the Placebo (Distilled water 25ml 3 
times daily). 
 There were 15 male and 16 female in Group I 
and 19 male and 12 female in Group II.  
 The age group of patients in Group I belonged to 
21 to 50, whereas 28 to 50 in Group II.  
 Fever being the main symptom, the temperature 
in the two groups ranged from a minimum of 
100.6° F to maximum of 103° F in Group I and 
101°F to 103° F in Group II. 
Seema Pradeep et al. Randomized Double Blind Placebo Controlled Clinical Study of Cymbopogan citratus in Influenza 
AYUSHDHARA | March - April 2020 | Vol 7 | Issue 2  2645 
 There was a drop in mean temperature in both 
groups seen before and after the treatment. (See 
details in Table 01 and Graph 1). 
 The details of temperature of all the 31 patients 
of the two groups is charted in table 03 & 04 and 
graph.  
 Other associated symptoms were recorded in the 
scoring scale of 10-0 and visual analogue scale 
for pains, details of their mean value of all 31 
patients in each group is charted in Table 04 and 
diagrammatically represented in graph 04. 
 Results of Statistical results: find the annexure.  
Results 
The signs and symptoms of Influenza 
showed improvement in patients when subjected to 
the Trial medication. The faster remissions of 
associated symptoms were seen in the trail group 
compared to the controlled group. The current 
study helped to prove the effect of Cymbopogon 
citratus (DC) Stapf in the disease influenza. This 
would help us create an increased awareness 
amongst the public about the use of herbal 
medicines in either cure or as add on therapy in the 
management of Influenza. 
Table 1: Showing parameters 
Parameters Group I  Group II 
Number of samples:  31 31 
Age 21- 50 28-50 
Gender 
Male 15 19 
Female 16 12 
Fever (Min- max) 100.6-103 101-103 
Fever (Mean in Degree F ) 
Before treatment 101.67 101.93 
After treatment 99.60968 99.74839 
Table 2: Showing- Temperature changes of the two groups, before and after treatment 
Group I  
 
Group II 
Fever (in Degree F) 
 
Fever (in Degree F) 
Subjects BT AT 
 
Subjects BT AT 
1 102.2 100 
 
1 102.2 100 
2 101 100 
 
2 102 100.2 
3 100.8 99 
 
3 102.8 100 
4 102.6 100 
 
4 102.4 100 
5 100.6 100 
 
5 101.8 99 
6 102.5 100.1 
 
6 102.2 100 
7 100.6 98.6 
 
7 101.2 100 
8 102 99 
 
8 102 100.2 
9 101 99 
 
9 101 99 
10 101.8 100 
 
10 102 98.8 
11 102 100.2 
 
11 102.6 100 
12 102 100 
 
12 101.2 100 
13 103 100 
 
13 101.8 99.2 
14 102 100 
 
14 101.6 100.1 
15 101.6 99 
 
15 102.1 100 
16 102 100 
 
16 102 100 
17 100.9 99 
 
17 101.8 99.8 
18 100.8 99.8 
 
18 101 100 
19 101.8 99.6 
 
19 103 99 
20 101 100 
 
20 102.4 100 
21 102.8 99 
 
21 102.2 99.6 
22 102 98 
 
22 102 100 
23 100.6 98.6 
 
23 102 99 
24 101.2 100 
 
24 102 100.1 
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25 102.6 99.6 
 
25 103 100 
26 101 100 
 
26 102 99.4 
27 102.3 100 
 
27 101 100 
28 100.8 100 
 
28 102.2 99 
29 100.8 100 
 
29 101.4 99.8 
30 103 100 
 
30 101.2 100 
31 102.6 99.4 
 
31 101.8 100 
Table 3: Showing- mean of the grades in associated symptoms of the two group, before and after 
treatment on a scoring scale of 10-0 
Associated Symptoms - (Average/ Mean ) 
Extreme coldness (chills shivering, shaking (rigor) 
Before treatment 0.7742 1.17 
After treatment 0 0 
Cough 
Before treatment 1.19 1.871 
After treatment 0 0.16129 
Nasal congestion 
Before treatment 0.29032 1.06452 
After treatment 0 0.03226 
Running nose 
Before treatment 2.67742 1.74194 
After treatment 0 0.0645 
Sneezing 
Before treatment 1.903 1.516 
After treatment 0 0 
Fatigue 
Before treatment 0.484 1.774 
After treatment 0 0.03 
Irritated, watering eyes 
Before treatment 0 0.3871 
After treatment 0 0.0645 
Redness in eyes/face/ mouth/throat/nose 
Before treatment 0.29032 0.3871 
After treatment 0 0.0645 
Body aches 
Before treatment 1.90323 3.19355 
After treatment 0 0 
Pain in Joints 
Before treatment 0.8065 1.2903 
After treatment 0 0 
Throat Ache 
Before treatment 0.6129 0.2903 
After treatment 0 0 
Headache 
Before treatment 1.871 1.1613 
After treatment 0 0 
Seema Pradeep et al. Randomized Double Blind Placebo Controlled Clinical Study of Cymbopogan citratus in Influenza 
AYUSHDHARA | March - April 2020 | Vol 7 | Issue 2  2647 
 
Lemon Grass 
Statistical Analysis of the study  
General Linear Model 
Descriptive Statistics 
Irrit_BT 
Groups Mean Std. Deviation N 
Trial .00 .000 31 
Control .39 1.230 31 
Irrit_AT 
Total .19 .884 62 
Trial .00 .000 31 
Control .06 .359 31 
Total .03 .254 62 
Tests of Within-Subjects Effects 
Measure: Measure_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change .806 1 .806 3.614 .062 
Change * groups .806 1 .806 3.614 .062 
Error (change) 13.387 60 .223   
The above table shows there is no significant difference found between the parameter of irritability between 
the trial group and control group.  
Profile Plots 
 
T-Test 
Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
Irrit_remission 
Trial 31 .00 .000 .000 
Control 31 .61 1.706 .306 
 
Independent Samples Test 
 t-test for Equality of Means 
t df Sig. (2-tailed) Mean Difference 
Irrit_remission -2.000 60 .050 -.613 
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The above table shows there is significant difference found between the parameter of fatigue remission with 
P value 0.050. The trial group was significantly better in irritability remission than control group. 
General Linear Model 
 
 
 
 
 
 
 
 
 
  
Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change 2.613 1 2.613 7.003 .010 
Change * groups .000 1 .000 .000 1.000 
Error (change) 22.387 60 .373   
The above table shows there is no significant difference found between the parameter of redness in between 
the trial and control group  
Profile Plots 
 
T-Test 
Group Statistics 
 groups N Mean Std. Deviation Std. Error Mean 
Redness_remission Trial 31 .32 1.013 .182 
Control 31 .45 1.207 .217 
The above table shows there is no significant difference found between the parameter of redness remission 
with the trial group and control group with P value 0.650 
General Linear Model 
Descriptive Statistics 
 Groups Mean Std. Deviation N 
Pete_rash_BT 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
Pete_rash_at 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
 
 
Descriptive Statistics 
 groups Mean Std. Deviation N 
Redness_BT 
Trial .29 .938 31 
Control .29 .783 31 
Total .29 .857 62 
Redness_AT 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
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Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change Sphericity Assumed .000 1 .000 . . 
Change * groups Sphericity Assumed .000 1 .000 . . 
Error (change) Sphericity Assumed .000 60 .000   
The above table shows no change  
Profile Plots 
 
T-Test 
Group Statistics 
 groups N Mean Std. Deviation Std. Error Mean 
Pete_rash_remission Trial 31 .00 .000a .000 
Control 31 .00 .000a .000 
a. t cannot be computed because the standard deviations of both groups are 0. 
General Linear Model 
Descriptive Statistics 
 Groups Mean Std. Deviation N 
Bodyache_BT 
Trial 1.90 2.226 31 
Control 3.19 2.212 31 
Total 2.55 2.295 62 
Bodyache_AT 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
 
Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change 201.323 1 201.323 81.742 .000 
Change * groups 12.903 1 12.903 5.239 .026 
Error (change) 147.774 60 2.463   
The above table shows there is significant difference found between the parameter of body pain in between 
trial and control group. The trial group was found to be significantly better than control group  
Profile Plots 
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T-Test 
Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
Bodyache_remission 
Trial 31 1.81 1.815 .326 
Control 31 3.71 2.003 .360 
 
Independent Samples Test 
 t-test for Equality of Means 
t df Sig. (2-tailed) Mean Difference 
Bodyache_remission -3.920 60 .000 -1.903 
The above table shows there is significant difference found between the parameter of fatigue remission. The 
trial group was significantly better in body ache remission than control group 
General Linear Model 
Descriptive Statistics 
 groups Mean Std. Deviation N 
Pain_BT 
Trial .81 1.515 31 
Control 1.33 1.768 30 
Total 1.07 1.652 61 
Pain_AT 
Trial .00 .000 31 
Control .00 .000 30 
Total .00 .000 61 
 
Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change 34.903 1 34.903 25.821 .000 
Change * groups 2.116 1 2.116 1.566 .216 
Error (change) 79.753 59 1.352   
The above table shows there is no significant difference found between the parameter of pain in between 
the trial and control group  
Profile Plots 
 
T-Test 
Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
Pain_remission 
Trial 31 .84 1.485 .267 
Control 31 1.97 2.415 .434 
 
Independent Samples Test 
 t-test for Equality of Means 
t df Sig. (2-tailed) Mean Difference 
Pain_remission -2.217 60 .030 -1.129 
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The above table shows there is significant difference found between the parameter of pain remission with P 
value 0.030.The trial group was significantly better in body ache remission than control group 
General Linear Model 
 
 
 
 
 
 
 
 
 
 
Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change 3.226 1 3.226 6.734 .012 
Change * groups .032 1 .032 .067 .796 
Error (change) 28.742 60 .479   
The above table shows there is no significant difference found between the parameter of throat pain in 
between the trial and control group 
Profile Plots 
 
T-Test 
Group Statistics 
 groups N Mean Std. Deviation Std. Error Mean 
Throat_remission 
Trial 31 .48 1.151 .207 
Control 31 .35 1.142 .205 
 
Independent Samples Test 
 t-test for Equality of Means 
t df Sig. (2-tailed) Mean Difference 
Throat_remission .443 60 .659 .129 
The above table shows there is no significant difference found between the parameter of throat pain 
remission in between the trial and control group  
General Linear Model 
Descriptive Statistics 
 Groups Mean Std. Deviation N 
Headache_BT 
Trial 1.87 2.109 31 
Control 1.16 2.018 31 
Total 1.52 2.078 62 
Headache_AT 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
Descriptive Statistics 
 groups Mean Std. Deviation N 
TThroat_BT 
Trial .35 .950 31 
Control .29 1.006 31 
Total .32 .971 62 
Throat_AT 
Trial .00 .000 31 
Control .00 .000 31 
Total .00 .000 62 
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Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source Type III Sum of Squares df Mean Square F Sig. 
Change 71.258 1 71.258 33.444 .000 
Change * groups 3.903 1 3.903 1.832 .181 
Error (change) 127.839 60 2.131   
The above table shows there is no significant difference found between the parameter of headache in 
between the trial and control group  
Profile Plots 
 
T-Test 
Group Statistics 
 groups N Mean Std. Deviation Std. Error Mean 
Headache_remission Trial 31 1.65 1.582 .284 
Control 31 1.29 2.101 .377 
 
Independent Samples Test 
 t-test for Equality of Means 
t df Sig. (2-tailed) Mean Difference 
Headache_remission .751 60 .455 .355 
The above table shows there is no significant difference found between the parameter of headache 
remission in between the trial and control group 
DISCUSSION  
The efficacy of the drug Cymbopogon 
citrates (DC.) Stapf in Influenza may be attributed to 
its pharmacological properties like Rasa Panchaka 
namely Katu,Tikta Rasa, Laghu Teekshna Guna, Katu 
Vipaka, Ushna Veerya and Karmas like Swedajanana, 
Jwaraghana, Deepana Paachana, Ruchya, 
Vatashamana, Shleshmaghna as mentioned in the 
Ayurveda classics[7]. The phyto constituents present 
in the drug like alkaloids, saponins, tannins and 
flavanoids are also supportive for the therapeutic 
activity of the drug. As there is faster remission 
seen in the trial group with respect to the 
associated symptoms of influenza this drug can be 
tried on a bigger sample size to prove its 
effectiveness on a wider scale. The drug being 
abundantly available makes it even more cost 
effective. Hence as shown in the current study due 
its better tolerance amongst the patients it can be 
aptly used as add on therapy in the management of 
influenza cases. 
CONCLUSION 
In Trial group, significantly better remission 
of associated signs and symptoms of influenza was 
found compared to control group. As paracetamol 
was used as rescue medicine in both the groups, no 
much significant difference was found between the 
trial and control group in the reduction of fever. The 
current study helped to confirm the effect of the 
plant Cymbopogon citrates (DC) Stapf in the disease 
influenza and proved to help sail through the course 
of illness with much ease.  
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Graph 1: Showing - Changes in temperature in the two groups: before and after treatment 
 
 
Graph 2: Showing - Changes in temperature of subjects in Group I : before and after treatment 
 
 
 
Graph 3: Showing - Changes in temperature of subjects in Group II: before and after treatment 
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Graph 4: Showing - Baseline characteristics of 62 patients their symptoms, who were randomized to 
receive the drug (Group I ) and Placebo (Group II) 
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